Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
The Open Analytical Ecosystem for Life Sciences
BioVerse is your pharma analytics platform — a modular ecosystem where clinical and biometrics teams move from exploration to submission without switching systems, rewriting work, or waiting months for a validated change.
Open. Validated. Owned by you.
Cytos
Infrastructure and platform
backbone
backbone
See more
Axon.R
R package validation,
GxP-aligned
GxP-aligned
See more
Tealfow
Clinical trial apps in hours,
not weeks
not weeks
See more
Mediforce
Human-AI collaboration
for regulated pharma
for regulated pharma
See more
Storage
Data ready for analysis
and AI
and AI
Coming Soon
Axon.Py
Py package validation,
GxP-aligned
GxP-aligned
Coming Soon
Results that compound across your organization
BioVerse is where modern platform engineering meets pharma regulatory expertise. It is designed to deliver at three layers: in how efficiently your teams work, in strategic control at the company level, and an architecture ready for what pharma analytics becomes over the next decade. A well-built analytics environment feels invisible when things work and unwavering when it counts.
Operational Acceleration
Your teams work with R, Python, and SAS across exploratory
and validated environments on the same architecture.
Strategic Advantages
You get an ecosystem you own, not a platform you rent.
When your cloud strategy changes, your environment changes with you.
Future-Ready
BioVerse’s architecture is designed for what comes next.
Built for scalability and adaptability.
The BioVerse ecosystem
BioVerse is an open analytical ecosystem for life sciences built on a layered, modular architecture. Each module stands on its own, but they share the same foundation. Adopt what you need.
Infrastructure and platform backbone
Cytos
Cytos is the compute fabric BioVerse runs on. It puts GxP and non-GxP work on one architecture.
See more
R package validation, GxP-aligned
Axon.R
Axon.R scores each R package for risk, runs it through the evidence and approval path, checks dependencies, and publishes to Posit Package Manager once the chain is valid.
See more
(Coming Soon)
Axon.Py
Axon.R's risk-based validation model, extended to Python. Axon.Py brings pandas, scikit-learn, PyMC, and the rest of the ML/AI stack inside the GxP boundary.
Human-AI collaboration for regulated pharma processes
Mediforce
Mediforce is an open-source platform for deploying AI agents into clinical and regulated processes.
See more
Clinical trial apps in hours, not weeks
TealFlow
TealFlow is Appsilon's GenAI clinical app builder. Describe what you need in plain language; TealFlow produces a working Shiny app that holds up in production.
See more
(Coming Soon)
Storage
The Storage module brings standardized ingestion, transformation, and lineage to the BioVerse architecture, so your data becomes ready for analysis and AI without losing the audit trail.
Innovation for Impact
Built for pharma analytics starting point
Every pharma organization we talk to is at a different point on the curve.
Pick a scenario that is close to your work.
01
"Our systems don't talk to each other"
SHINY FOR R & PYTHON
"Our systems don't talk to each other"
The near-database-lock scramble you already recognize.
Disconnected systems mean data shuffled through Excel exports, with issues surfacing right before database lock when fixes are expensive.
BioVerse runs validated and exploratory work in one cloud-native environment — one auth model, one audit trail.
02
"Our SCE is 10+ years of patchwork"
CUSTOM INFRASTRUCTURE
"Our SCE is 10+ years of patchwork"
Incremental upgrades don't rescue a patchwork core.
Decade-old environments accumulate tools and opaque data flows. On-prem is expensive, but modernization drowns in validation scope.
BioVerse is built for this migration. Cytos is cloud-native, infrastructure-as-code, deployed under your policies — reproducible and auditable. R, Python, and SAS run side-by-side. Storage and compute are modular, and partners plug in cleanly because the architecture is open at the core.
03
"We're moving from outsourced to in-house"
OPEN SOURCE
"We're moving from outsourced to in-house"
Build the internal capability without waiting three years for cloud migration to finish.
Statistical programming runs on manual-QA SaaS, with biostats, PK/PD, and biomarker teams scattered. Cloud migration won't finish before your next submission.
BioVerse deploys as an intermediate layer that survives the transition. GxP and non-GxP share one architecture, teams work in SAS, R and Python, and package validation goes from manual to Axon-automated on day one. When migration finishes, BioVerse moves with you.
Runs on AWS, Azure, or GCP. You own the deployment.
04
"We're building from zero"
GXP COMPILANCE
"We're building from zero"
A cloud-native, AI-ready SCE, deployed end-to-end.
You're a clinical-stage biotech with no legacy SAS or on-prem to phase out. You want infrastructure designed right the first time: validated, cloud-native, AI-ready.
BioVerse ships as a complete stack: Cytos for the SCE, Axon for package validation, Posit for analytics — deployed in your cloud from day one. Our team showed how to go from no SCE to regulated clinical work in six months at PHUSE US Connect 2026.
Timelines depend on context: existing infrastructure, team readiness, validation scope, regulatory posture. What we built for our clients, we can build for you.
#Valued by clients worldwide
#Configured for you. Owned by you
Evolution of Validation
Continuous Risk-Based Validation
Monolithic Validation
✅ Snapshot Agility
Teams are stuck with old versions of R and libraries, missing out on new scientific methods.
❌ System Lock-in
Teams are stuck with old versions of R and libraries, missing out on new scientific methods.
✅ Automated QA
Teams are stuck with old versions of R and libraries, missing out on new scientific methods.
❌ Validation "Theatre"
Teams are stuck with old versions of R and libraries, missing out on new scientific methods.
✅ Fully deployable - includes AWS setup, CI/CD, and SSO integration.
Teams are stuck with old versions of R and libraries, missing out on new scientific methods.
❌ Innovation Lag
Teams are stuck with old versions of R and libraries, missing out on new scientific methods.
#Contact Form
Consult with Our Experts for Custom Solutions
Get in touch
with Appsilon Experts
with Appsilon Experts
We will contact you within 24 hours!
#Our Clients About Appsilon
How It Feels to Work with Us
We rely on Appsilon's expertise to support the build and maintenance of critical clinical reporting software based in R and Shiny.
Data Engineering Lead
Top 10 Pharma Company
Appsilon team is exceptional. The engineers challenge and speak their minds, which helps do justice to the product
Associate Director
Top 50 Pharma Company
We wouldn’t be here where we are now without Appsilon. I want this partnership to keep going and growing.
Human Resources People Partner
Top 10 Pharma Company
Expert Insights
Insights, Inspiration & Distilled Knowledge
Pharma Is Not Leaving SAS Because It Stopped Working. It's Leaving Because Open Source Moves Faster.
Novo Nordisk, Roche, GSK, Johnson & Johnson: the biggest names in pharma have moved off SAS. This post breaks down what's actually driving that shift, what open source delivers beyond cost savings, and what separates a successful transition from one that stalls.
Appsilon Team
Read more
Why Most Statistical Computing Environments in Pharma Weren't Built for What's Coming Next
Most statistical computing environments in pharma were designed when SAS was the default language, studies were simpler, timelines were longer, and "open source in regulated settings" was still a controversial idea.
Rafael Pereira
Read more
What Is a Statistical Computing Environment (SCE) in Pharma?
If you work in clinical development, you probably hear “SCE” in every other meeting about infrastructure, compliance, or moving off SAS. The acronym gets used loosely. Sometimes it means one specific tool. Sometimes it means an entire ecosystem. Sometimes it’s shorthand for “the thing our statisticians open every morning.”
Ileana Saenz
Read more
FAQs
Find clear answers to common questions about GxP compliance, helping you navigate regulations with confidence.
01.
What is BioVerse?
BioVerse is Appsilon's open analytical ecosystem for life sciences, a modular platform for clinical R&D where GxP and non-GxP work share one architecture. It's built from independent modules: Cytos for the statistical computing environment, Axon for validation, TealFlow for clinical apps, Mediforce for regulated AI, and Storage for modern clinical data engineering. Adopt what you need.
02.
How does BioVerse relate to the idea of a statistical computing environment (SCE)?
Cytos is the SCE layer and compute fabric of BioVerse. If you're looking specifically at SCE modernization, Cytos is the module that covers it: cloud-native infrastructure, Posit Workbench for R, Python, and SAS, Package Manager, Connect, and the deployment pipeline. BioVerse extends around Cytos: validation (Axon), clinical apps (TealFlow), regulated AI (Mediforce), and a Storage module on the roadmap.
03.
Can I choose our own analytics stack, or are we locked in?
BioVerse is analytics-stack-agnostic. The current deployment runs the Posit stack: Workbench, Connect, Package Manager. Altair SLC is architecturally integrated for clients who need it. The Cytos layer accepts whichever analytics stack you choose to run, and infrastructure-as-code means adding another one is a configuration change rather than a rebuild.
04.
Do we own the environment or are we renting it from Appsilon?
You own it. BioVerse deploys on your cloud (AWS, Azure, or GCP) with infrastructure-as-code you can read and modify. There are no SaaS fees and no black-box layers. Appsilon builds and extends the environment with you, but the deployment belongs to your organization.
05.
What's the deployment model? How long does a typical engagement take?
A typical engagement starts with an architecture conversation and moves into discovery: which modules fit first, what existing infrastructure to preserve, what validation scope looks like. Implementation timelines depend heavily on context. A greenfield biotech can reach operational, regulated work in months. A large-pharma migration off a decade-old on-premise stack is a longer, phased program. We showed a six-month greenfield case at PHUSE US Connect 2026. Your mileage will vary.
06.
How does BioVerse work with the infrastructure we already have?
BioVerse is built to interoperate with what you already run. It sits alongside existing clinical data management, standards, and reporting tooling via standard interfaces. Migrating from an aging on-premise SCE is one of our core use cases. For large pharma clients, the first year is often about running BioVerse in parallel with legacy systems while specific workflows migrate study-by-study.
07.
I'm looking for an out-of-the-box SCE solution due to limited IT capacity. Is BioVerse right for my organization?
BioVerse isn't a SaaS platform you spin up yourself. But limited IT capacity is exactly why teams come to us; because we dothe heavy lifting.BioVerse is a system of modular components: analytics workspace, validation layer, AI tools, data infrastructure.
Appsilon assembles your SCE out of them. You choose the modules your organization actually needs. We architect, configure, and validate the environment. Your IT team defines the requirements; they don't have to build or maintain a complex clinical infrastructure stack.In some cases, we're open for hosting environments for you.
Talk to our team, and we'll scope the right setup for your organization.
Contact Us
Drive Impact with Appsilon
BioVerse is built with pharma and biotech clients, not in a lab. If you're planning an SCE modernization, scoping an R/Python migration, or building an analytical environment from zero — we can help you figure out what the right next step looks like for your team.